We performed six classification tasks, including (i) tumor vs. normal, (ii) lobular vs. ductal carcinoma histological type, (iii) estrogen receptor (ER) status (positive or negative), (iv) progesterone receptor (PR) status (positive or negative), (v) HER2 receptor status (positive or negative), (vi) PAM50 four-way status (Luminal A, Luminal B, Basal, or HER2 enriched), and (vii) TP53 Mutation status. The gene discussed is PGR; the disease is neoplasm.